Free Trial
NASDAQ:MTSR

Metsera (MTSR) Stock Price, News & Analysis

Metsera logo
$27.59 -0.42 (-1.50%)
As of 04:00 PM Eastern

About Metsera Stock (NASDAQ:MTSR)

Key Stats

Today's Range
$27.00
$28.60
50-Day Range
$13.08
$30.01
52-Week Range
$12.30
$32.81
Volume
778,022 shs
Average Volume
886,447 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00
Consensus Rating
Buy

Company Overview

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Receive MTSR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter.

MTSR Stock News Headlines

Cantor Fitzgerald maintains overweight on Metsera shares
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
Metsera Rings the Opening Bell
See More Headlines

MTSR Stock Analysis - Frequently Asked Questions

Metsera's stock was trading at $29.50 on January 1st, 2025. Since then, MTSR shares have decreased by 6.5% and is now trading at $27.59.
View the best growth stocks for 2025 here
.

Metsera, Inc. (NASDAQ:MTSR) announced its quarterly earnings data on Monday, May, 12th. The company reported ($1.03) EPS for the quarter.

Metsera (MTSR) raised $275 million in an initial public offering on Friday, January 31st 2025. The company issued 15,277,778 shares at $18.00 per share.

Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its public offering on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Top institutional investors of Metsera include Alphabet Inc. (4.72%), T. Rowe Price Investment Management Inc. (2.75%), Wellington Management Group LLP (2.29%) and Alpha Wave Global LP (2.27%).

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/12/2025
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MTSR
Previous Symbol
NASDAQ:MTSR
Web
N/A
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.00
High Stock Price Target
$56.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+70.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$2.90 billion
Optionable
N/A
Beta
N/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:MTSR) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners